192 related articles for article (PubMed ID: 28545804)
41. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide.
Agertoft L; Pedersen S
J Allergy Clin Immunol; 2005 May; 115(5):940-5. PubMed ID: 15867849
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
Adachi M; Goldfrad C; Jacques L; Nishimura Y
Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
[TBL] [Abstract][Full Text] [Related]
43. Methodology and implications of knemometry in growth assessment of inhaled glucocorticoids.
Wolthers OD
Pediatr Allergy Immunol; 2010 Feb; 21(1 Pt 2):e190-8. PubMed ID: 19422602
[TBL] [Abstract][Full Text] [Related]
44. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate.
Agertoft L; Pedersen S
Pediatr Allergy Immunol; 2010 Feb; 21(1 Pt 2):e199-205. PubMed ID: 19320851
[TBL] [Abstract][Full Text] [Related]
45. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial.
Woodcock A; Bateman ED; Busse WW; Lötvall J; Snowise NG; Forth R; Jacques L; Haumann B; Bleecker ER
Respir Res; 2011 Oct; 12(1):132. PubMed ID: 21977941
[TBL] [Abstract][Full Text] [Related]
46. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
47. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
[TBL] [Abstract][Full Text] [Related]
48. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
Harnest U; Price D; Howes T; Sussman G
J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
[TBL] [Abstract][Full Text] [Related]
49. Knemometry is more sensitive to systemic effects of inhaled corticosteroids in children with asthma than 24-hour urine cortisol excretion.
Chawes B; Nilsson E; Nørgaard S; Dossing A; Mortensen L; Bisgaard H
J Allergy Clin Immunol; 2017 Aug; 140(2):431-436. PubMed ID: 28012663
[TBL] [Abstract][Full Text] [Related]
50. Calculation of knemometric growth rates in group studies of children treated with exogenous glucocorticoids.
Heuck C; Wolthers OD
Ann Hum Biol; 1997; 24(5):411-8. PubMed ID: 9300118
[TBL] [Abstract][Full Text] [Related]
51. Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial.
Daley-Yates P; Keppler B; Baines A; Bardsley G; Fingleton J
Respir Res; 2022 Sep; 23(1):258. PubMed ID: 36127726
[TBL] [Abstract][Full Text] [Related]
52. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis.
Skoner DP; Gentile D; Angelini B; Kane R; Birdsall D; Banerji D
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):56-62. PubMed ID: 12546339
[TBL] [Abstract][Full Text] [Related]
53. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
Sharpe M; Jarvis B
Drugs; 2001; 61(9):1325-50. PubMed ID: 11511026
[TBL] [Abstract][Full Text] [Related]
54. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.
Albertson TE; Richards JR; Zeki AA
Ther Adv Respir Dis; 2016 Feb; 10(1):43-56. PubMed ID: 26668137
[TBL] [Abstract][Full Text] [Related]
55. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
Yang S; Lee L; Mallett S; Ayer J; Wolstenholme A; Pascoe S
Adv Ther; 2015 Feb; 32(2):157-71. PubMed ID: 25700806
[TBL] [Abstract][Full Text] [Related]
56. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.
Lee DK; Fardon TC; Bates CE; Haggart K; McFarlane LC; Lipworth BJ
Chest; 2005 Mar; 127(3):851-60. PubMed ID: 15764767
[TBL] [Abstract][Full Text] [Related]
57. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
58. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
[TBL] [Abstract][Full Text] [Related]
59. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids.
Kerwin EM; Gillespie M; Song S; Steinfeld J
J Asthma; 2017 Jan; 54(1):89-98. PubMed ID: 27285965
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
Mehta R; Moore A; Riddell K; Joshi S; Chan R
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
